Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

GlobeNewsWire • Feb 12, 2026

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m.

GlobeNewsWire • Feb 4, 2026

This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth

With the tech sector coming under pressure many are looking for alternative investment areas. This pharma stock is an option worth considering.

Investors Business Daily • Jan 30, 2026

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Seeking Alpha • Dec 10, 2025

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002 Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate $1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor Day in New York City today.

GlobeNewsWire • Dec 9, 2025

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based business model.

Investors Business Daily • Nov 18, 2025

This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable assets under management at quarter-end.

The Motley Fool • Nov 17, 2025

Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come

Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a key driver of its outperformance and future investment appeal. This article evaluates LGND's ongoing investment prospects in light of its recent substantial price appreciation.

Seeking Alpha • Nov 13, 2025

Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.

Seeking Alpha • Nov 8, 2025

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Third quarter performance driven by strong portfolio royalty revenue growth of  47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share 1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

GlobeNewsWire • Nov 6, 2025